Roche’s KRAS blocker touts best-in-class NSCLC potential in Phase III trial
Divarasib outperformed existing therapies in patients with KRAS G12C non-small cell lung cancer (NSCLC).
02 July 2026
02 July 2026
Divarasib outperformed existing therapies in patients with KRAS G12C non-small cell lung cancer (NSCLC).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.